Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer
Retsky et al APMIS 2008.pdf (249.4Kb)
Access StatusFull text of the requested work is not available in DASH at this time ("dark deposit"). For more information on dark deposits, see our FAQ.
Hrushesky, W. J. M.
Gukas, I. D.
MetadataShow full item record
CitationRetsky, M. W., R. Demicheli, W. J. M. Hrushesky, M. Baum, and I. D. Gukas. 2008. “Dormancy and Surgery-Driven Escape from Dormancy Help Explain Some Clinical Features of Breast Cancer .” APMIS 116 (7-8) (July): 730–741. doi:10.1111/j.1600-0463.2008.00990.x.
AbstractTo explain bimodal relapse patterns observed in breast cancer data, we have proposed that metastatic breast cancer growth commonly includes periods of temporary dormancy at both the single cell phase and the avascular micrometastasis phase. The half-lives of these states are 1 and 2 years respectively. We also suggested that surgery to remove the primary tumor often terminates dormancy resulting in accelerated relapses. These iatrogenic events are very common in that over half of all metastatic relapses progress in that manner. Assuming this is true, there should be ample and clear evidence in clinical data. We review here the breast cancer paradigm from early detection, through treatment and follow-up, and consider how dormancy and surgery-driven escape from dormancy would be observed. We examine mammography data, effectiveness of adjuvant chemotherapy, heterogeneity and aggressiveness, timing of surgery within the menstrual cycle and racial differences in outcome. Dormancy can be identified in these diverse data but most conspicuous is the sudden escape from dormancy following primary surgery. These quantitative findings provide linkage between experimental studies of tumor dormancy and clinical efforts to improve patient outcome.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:34903210
- SPH Scholarly Articles